{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:39:07Z","timestamp":1794299947303,"version":"4.9.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ibroneuroscience.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.neuroscience.2024.11.029","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T21:08:41Z","timestamp":1731618521000},"page":"29-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer \u2019s disease: A systematic review and network meta- analysis"],"prefix":"10.1016","volume":"565","author":[{"given":"Weili","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naibing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongye","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanya","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengli","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7955","key":"10.1016\/j.neuroscience.2024.11.029_b0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/d41586-023-00954-w","article-title":"Conquering Alzheimer's: a look at the therapies of the future","volume":"616","author":"Abbott","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.029_b0010","first-page":"367","article-title":"2018Alzheimer's disease facts and figures","volume":"14","author":"AsdtjotAs","year":"2018","journal-title":"Alzheimers Dementia"},{"key":"10.1016\/j.neuroscience.2024.11.029_b0015","article-title":"Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner","volume":"191","author":"Bosch","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0020","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer\u2019s therapeutic development: the past and future of clinical trials","volume":"18622","author":"Boxer","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2024.11.029_b0025","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/jnnp.2009.204008","article-title":"The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts","volume":"8112","author":"Cano","year":"2010","journal-title":"J. Neurol. Neurosurg. Psych."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.029_b0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0035","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1093\/brain\/awac096","article-title":"Reimagining cholinergic therapy for Alzheimer\u2019s disease","volume":"1457","author":"Giacobini","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2024.11.029_b0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41401-024-01293-w","article-title":"Sodium oligomannate activates the enteroendocrine-vagal afferent pathways in APP\/PS1 mice","author":"Gong","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"21","key":"10.1016\/j.neuroscience.2024.11.029_b0045","doi-asserted-by":"crossref","first-page":"11791","DOI":"10.3390\/ijms222111791","article-title":"Combination of the glutaminyl cyclase inhibitor PQ912 (Varoglutamstat) and the murine monoclonal antibody PBD-C06 (m6) shows additive effects on brain A\u03b2 pathology in transgenic mice","volume":"22","author":"Hoffmann","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0050","article-title":"Combination of the glutaminyl cyclase inhibitor PQ912 (varoglutamstat) and the murine monoclonal antibody PBD-C06 (m6) shows additive effects on brain A\u03b2 pathology in transgenic mice","volume":"2221","author":"Hoffmann","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102348","article-title":"Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit","volume":"99","author":"H\u00f8ilund-Carlsen","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0060","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer's disease modification","volume":"178","author":"Izzo","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"issue":"10","key":"10.1016\/j.neuroscience.2024.11.029_b0065","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0895-4356(88)90034-0","article-title":"A Chinese version of the mini-mental state examination; impact of illiteracy in a Shanghai dementia survey","volume":"41","author":"Katzman","year":"1988","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0070","article-title":"Natural products from plants and algae for treatment of Alzheimer\u2019s disease: a review","volume":"125","author":"Klose","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuroscience.2024.11.029_b0075","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1192\/bjp.2023.166","article-title":"Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK","volume":"2246","author":"Laurell","year":"2024","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuroscience.2024.11.029_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106575","article-title":"An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease","volume":"199","author":"Lizama","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0085","first-page":"1","article-title":"Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging","author":"Lowe","year":"2021","journal-title":"J. Prevent. Alzheimer's Dis."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0090","article-title":"Alzheimer's disease: clinical trials and drug development published correction appears in Lancet Neurol. 2011 Jun;10(6):501","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0095","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"141","author":"McDade","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0100","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"38418","author":"Mintun","year":"2021","journal-title":"New England J. Med."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0105","article-title":"Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease","volume":"1027","author":"Nguyen","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2024.11.029_b0110","article-title":"Potential beneficial effects of masupirdine (SUVN-502) on agitation\/aggression and psychosis in patients with moderate Alzheimer's disease: exploratory post hoc analyses","volume":"3710","author":"Nirogi","year":"2022","journal-title":"Int. J. Geriatr. Psych."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0115","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s40120-022-00390-4","article-title":"Effect of concurrent use of memantine on the efficacy of masupirdine (SUVN-502): a post hoc analysis of a phase 2 randomized placebo-controlled study","volume":"114","author":"Nirogi","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0120","article-title":"Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: a randomized, double-blind, phase 2, proof-of-concept study","volume":"81","author":"Nirogi","year":"2022","journal-title":"Alzheimer's & Dementia: Transl. Res. Clin. Intervent."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0125","article-title":"Progress in investigational agents targeting serotonin-6 receptors for the treatment of brain disorders","volume":"132","author":"Nirogi","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuroscience.2024.11.029_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1249018","article-title":"Polysaccharides: potential bioactive macromolecules for Alzheimer\u2019s disease","volume":"10","author":"Peng","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0135","unstructured":"Proceedings of the National Academy of Sciences."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0140","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2024.11.029_b0145","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"131","author":"Swanson","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.029_b0150","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40265-020-01268-1","article-title":"Sodium oligomannate: first approval [published correction appears in Drugs. 2020 Mar;80(4):445-446. doi: 10.1007\/s40265-020-01274-3","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.neuroscience.2024.11.029_b0155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40265-020-01268-1","article-title":"Sodium oligomannate: first approval","volume":"804","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.neuroscience.2024.11.029_b0160","article-title":"Cross-sectional and longitudinal assessments of function in prodromal-to-mild Alzheimer's disease: a comparison of the ADCS-ADL and A-IADL-Q scales","volume":"152","author":"Teng","year":"2023","journal-title":"Alzheimer's & Dementia: Diagnos., Assess. Disease Monitor."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102203","article-title":"Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: a systematic review and network meta-analysis","volume":"94","author":"Terao","year":"2024","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.029_b0170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","volume":"12","author":"Tolar","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"3881","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0180","article-title":"A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer\u2019s disease","volume":"161","author":"van Dyck","year":"2024","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0185","article-title":"A phase II randomized trial of sodium oligomannate in Alzheimer\u2019s dementia","volume":"121","author":"Wang","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"10","key":"10.1016\/j.neuroscience.2024.11.029_b0190","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0195","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression","volume":"2910","author":"Wang","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101655","article-title":"The future of stem cell therapies of Alzheimer\u2019s disease","volume":"80","author":"Wang","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0205","article-title":"A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer\u2019s dementia","volume":"131","author":"Xiao","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0210","article-title":"GV-971 attenuates the progression of neuromyelitis optica in murine models and reverses alterations in gut microbiota and associated peripheral abnormalities","volume":"307","author":"Yang","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0215","article-title":"Passive immunotherapy for Alzheimer\u2019s disease: challenges & future directions","volume":"221","author":"Yi","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.neuroscience.2024.11.029_b0220","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future","volume":"81","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224006110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224006110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T20:42:13Z","timestamp":1736196133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452224006110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":44,"alternative-id":["S0306452224006110"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.11.029","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer \u2019s disease: A systematic review and network meta- analysis","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of International Brain Research Organization (IBRO).","name":"copyright","label":"Copyright"}]}}